electroCore completes acquisition of NeuroMetrix; $4.49/share plus CVRs

electroCore, Inc.

Cash consideration of $4.49 per NURO share; each share also gets one CVR tied to Quell sales milestones.
CVR payments include 8% of Quell Net Sales up to $500K in first year, 6% in second year, plus DPNCheck proceeds.
electroCore gains Quell Fibromyalgia Solution, expects to leverage VA Hospital System distribution channel.
NURO shares to be de-listed from Nasdaq Capital Market before trading on May 2, 2025.
Transaction approved by NURO stockholders on March 21, 2025; closed May 1, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.